Mattel introduces first Barbie with type 1 diabetes
(WJW) – The first Barbie doll with type 1 diabetes is making her debut, the toy giant Mattel, Inc. announced on Tuesday.
The company shared a first look at the newest Barbie, featuring a blue polka dot dress for diabetes awareness, a continuous glucose monitor (CGM) on her arm and an insulin pump.
Mattel said the latest edition helps young children with diabetes to see themselves in Barbie 'and encourages doll play that extends beyond a child's own lived experience.'
What to know about the new school cell phone policy in Ohio
'Introducing a Barbie doll with type 1 diabetes marks an important step in our commitment to inclusivity and representation,' Krista Berger, Senior Vice President of Barbie and Global Head of Dolls said in a press release. 'Barbie helps shape children's early perceptions of the world, and by reflecting medical conditions like T1D, we ensure more kids can see themselves in the stories they imagine and the dolls they love.'
Barbie partnered with the organization Breakthrough T1D to bring the new doll to life (figuratively). The organization focuses on research to help speed up breakthroughs in type 1 diabetes treatment and prevention.
Company officials said they worked closely with Breakthrough T1D to make sure the new Barbie best represents people with the condition.
Extra itchy, swollen mosquito bites? You could have Skeeter syndrome
Barbie also donated dolls to the Breakthrough T1D 2025 Children's Congress, an event that brings 170 children with type 1 diabetes to meet with congress members, the release said.
Mattel officials said the new Barbie dolls are already available online and in retail stores across the country.
According to the Cleveland Clinic, type 1 diabetes, diagnosed in both children and adults, is 'a chronic autoimmune disease that prevents your pancreas from making insulin.' It is considered one of the most common chronic diseases to affect kids in the United States.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Teething 9-Month-Old Has Strange Bump in His Mouth. Docs Think It's a Tumor Until They See a Toy Embedded in His Gums
Rowan Steiner says 5 doctors examined the blue mass in her son's mouth before a specialist used a dental tool to pry it off A mom was changing her baby's diaper when she saw something that scared her. Rowan Steiner, 31, said her son, Max, then 9 months, was crying during the diaper change — and that's when she spotted a massive blue lump by his gums. The Salt Lake City, Utah, mom of five said she and her husband rushed her son to the hospital, where he spent 12 hours being examined by five different doctors, according to Daily Mail. Kennedy News & Media Part of a fidget toy that was in 9-month-old Max Steiner's mouth The PEOPLE App is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! Docs originally thought it was a tumor but admitted it could be something else. ADVERTISEMENT 'Throughout the day the doctors had mentioned it could be a toy. We were totally open to the idea because I have five children and a nine-month-old wants to put everything in their mouth at that stage,' Steiner said of the 2022 ordeal. But, 'I, his dad, and all of the doctors physically touched it ... every single person did.' One doctor even said Max needed a CT scan. But when an ear, nose, and throat specialist examined Max, he used a dental tool to pry the 'mass' off — and the Steiners discovered it was a bubble from a fidget toy that had come loose while the tot was sucking on it. Getty Stock image of a fidget toy. 'It was just suctioned so tightly that it wasn't moving at all,' Steiner told the outlet. 'We were like, 'How would this make sense?' A fidget toy was not what we were thinking of at all." 'We were terrified, and then when we found out it was a fidget toy, we were relieved.' ADVERTISEMENT Max had some swelling and bleeding around his gums after the plastic bubble was removed, but his mom shares, 'That was probably the best case scenario after thinking that it was going to be a tumor, or he could have swallowed it or choked on it.' Never miss a story — sign up for PEOPLE's free daily newsletter to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Read the original article on People
New York Times
25 minutes ago
- New York Times
Oxygen Machine Played Role in Fire That Killed 10 in Massachusetts, Officials Say
A fire that killed 10 people at an assisted living center in Fall River, Mass., this month began in a resident's second-floor room, where investigators found an oxygen machine and 'smoking materials,' officials said Tuesday. The presence of medical oxygen 'played a significant role' in the rapid start and spread of the fire on July 13 at the facility, Gabriel House, Jon Davine, the Massachusetts state fire marshal, said at a news conference. 'Smoking is especially dangerous when home oxygen is in use,' Mr. Davine said. 'No one should smoke around medical oxygen.' Officials said the fire was accidental. Thomas M. Quinn III, the district attorney for Bristol County, said that a preliminary examination of the scene and initial interviews, as well as additional evidence gathered in the last week, show that 'the fire did not appear to be set intentionally.' Investigators determined the fire began in a resident's room on the left side of the facility's second floor, Mr. Davine said. There were no signs that the fire was caused by cooking, lighting, heating, electrical outlets or appliances in the room, or by candles or incense, he said. But investigators found an oxygen concentrator — a medical device that filters oxygen from the air — and 'numerous smoking materials,' in the room, Mr. Davine said. An electrical or mechanical failure involving the oxygen concentrator, or the improper use or disposal of smoking materials, were identified as the two possible causes of the fire, Mr. Davine said. Want all of The Times? Subscribe.
Yahoo
an hour ago
- Yahoo
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
Eupraxia's EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: . Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas. Story Continues Notice Regarding Forward-looking Statements and Information This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "suggests", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the expected enrollment and number of sites for the Phase 2b portion of the RESOLVE study; the expected parameters of the RESOLVE study; the availability of topline data and release of additional long-term data with higher doses and timing thereof; the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the expectations around proceeding to clinical trials for the Company's product candidates; the results gathered from studies and trials of Eupraxia's product candidates; the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company's product candidates; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company's active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ ( and EDGAR ( Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise. For investor and media inquiries, please contact: Danielle Egan, Eupraxia Pharmaceuticals Inc. 778.401.3302 degan@ or Kevin Gardner, on behalf of: Eupraxia Pharmaceuticals Inc. 617.283.2856 kgardner@ SOURCE Eupraxia Pharmaceuticals Inc.
